Q J Exp Psychol (Hove)
October 2024
Intentional inhibition, the ability to voluntarily inhibit or suspend an action preparation, is closely related to self-control. It is widely believed that subliminal stimuli can also activate action preparation, but whether intentional inhibition is enhanced or disrupted with greater subliminal action preparation remains unclear. In this study, participants voluntarily decided whether or not to perform the action in the scenario with subliminal action preparation, and the strength of the action preparation was manipulated by a precueing procedure.
View Article and Find Full Text PDFHuman sulfotransferases 1A3 (SULT1A3) has received particular interest, due to their functions of catalyzing the sulfonation of numerous phenolic substrates, including bioactive endogenous molecules and therapeutic agents. However, the regulation of SULT1A3 expression and the underlying mechanism remain unclear. Here, we aimed to investigate the regulation effects of bile acid-activated farnesoid X receptor (FXR) on SULT1A3 expression, and to shed light on the mechanism thereof.
View Article and Find Full Text PDFUnderstanding the mechanisms regulating PD-L1 expression in hepatocellular carcinoma (HCC) is important to improve the response rate to PD-1/PD-L1 blockade therapy. Here, we show that DKK1 expression is positively associated with PD-L1 expression and inversely correlated with CD8 T cell infiltration in human HCC tumor specimens. In a subcutaneous xenograft tumor model, overexpression of DKK1 significantly promotes tumor growth, tumoral PD-L1 expression, but reduces tumoral CD8 T cell infiltration; whereas knockdown of DKK1 has opposite effects.
View Article and Find Full Text PDFBackground: Spermine is frequently elevated in tumor tissues and body fluids of cancer patients and is critical for cancer cell proliferation, migration and invasion. However, the immune functions of spermine in hepatocellular carcinoma progression remains unknown. In the present study, we aimed to elucidate immunosuppressive role of spermine in hepatocellular carcinoma and to explore the underlying mechanism.
View Article and Find Full Text PDFNeratinib, an irreversible pan-HER tyrosine kinase inhibitor, has been approved for the treatment of HER2-positive (HER2) early-stage and brain metastatic breast cancer. Thus far, the pharmacology effects and pharmacodynamics of neratinib have been well studied. However, the disposition of neratinib and its influencing factors in vivo remain unclear.
View Article and Find Full Text PDF